Which organism group is specifically mentioned in relation to reduced vancomycin use when rapid diagnostics are used?

Which organism group is specifically mentioned in relation to reduced vancomycin use when rapid diagnostics are used?

• A. MRSA
• B. Enterococcus faecalis
• C. Escherichia coli
• D. Coagulase-negative staphylococci

Answer: (D)

Rapid diagnostics let clinicians tailor therapy by quickly identifying the organism and its resistance pattern, which supports narrowing or stopping broad-spectrum drugs like vancomycin. Coagulase-negative staphylococci are frequently encountered in blood cultures and are often contaminants or less virulent pathogens; when rapid tests indicate CNS, clinicians can more confidently de-escalate vancomycin in many cases, avoiding unnecessary exposure. The other listed organisms don’t have this same common link to rapid-diagnostic–driven de-escalation: MRSA is typically a target for vancomycin rather than a group whose rapid identification routinely reduces vancomycin use, and Enterococcus faecalis or Escherichia coli involve different therapeutic decision points.

Rapid diagnostics let clinicians tailor therapy by quickly identifying the organism and its resistance pattern, which supports narrowing or stopping broad-spectrum drugs like vancomycin. Coagulase-negative staphylococci are frequently encountered in blood cultures and are often contaminants or less virulent pathogens; when rapid tests indicate CNS, clinicians can more confidently de-escalate vancomycin in many cases, avoiding unnecessary exposure. The other listed organisms don’t have this same common link to rapid-diagnostic–driven de-escalation: MRSA is typically a target for vancomycin rather than a group whose rapid identification routinely reduces vancomycin use, and Enterococcus faecalis or Escherichia coli involve different therapeutic decision points.